BridgeMD
New treatment option for Kidney Stones
Official title SGLT2i in Kidney Stones
ClinicalTrials.gov ID: NCT07055282
What this study is testing
What is Empagliflozin (Jardiance®)?
Empagliflozin (Jardiance®) is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for kidney stones.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is looking at whether empagliflozin, a medication typically used for diabetes and heart conditions, may affect factors that contribute to kidney stone formation. The research focuses on people who have had calcium-based kidney stones, i.e.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Calcium phosphate (CaP) stone participants:
- Age 18-70
- History of at least one calcium phosphate (hydroxyapatite) stone
- Defined as at least 50% of stone material on most recent stone analysis Calcium oxalate (CaOx) stone participants:
- Age 18-70
You likely can't join if
- History of primarily brushite, uric acid, cysteine, or struvite stones
- History of severe acid-base abnormality, very low (less than 100mg/day) or very high (greater than 1500mg/day) urine citrate
- Participants who cannot stop diuretic medication or alkali supplementation for the course of the study period
- Use of drugs that can directly affect proximal tubule function (e.g., topiramate)
- Diagnosis of complete distal renal tubular acidosis
- Diagnosis of chronic kidney disease (eGFR \<60 mL/min/1.73m²)
See the full eligibility criteria
- Calcium phosphate (CaP) stone participants:
- Age 18-70
- History of at least one calcium phosphate (hydroxyapatite) stone
- Defined as at least 50% of stone material on most recent stone analysis Calcium oxalate (CaOx) stone participants:
- Age 18-70
- History of at least one calcium oxalate stone
- Defined as at least 50% of stone material on most recent stone analysis. Other considerations: The investigators will study balanced numbers of male and females. Prior studies did not have balanced representation of...
- History of primarily brushite, uric acid, cysteine, or struvite stones
- History of severe acid-base abnormality, very low (less than 100mg/day) or very high (greater than 1500mg/day) urine citrate
- Participants who cannot stop diuretic medication or alkali supplementation for the course of the study period
- Use of drugs that can directly affect proximal tubule function (e.g., topiramate)
- Diagnosis of complete distal renal tubular acidosis
- Diagnosis of chronic kidney disease (eGFR \<60 mL/min/1.73m²)
The study team makes the final eligibility decision.
Where it's taking place
- Chicago, Illinois, United States
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chicago, Illinois, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.